First NCFB patient dosed in Phase IIa study of RESP-X
Potential first-in-class anti-virulence antibody drug to reduce the frequency of debilitating exacerbations in respiratory patients with…
Infex invites you to Alderley Park’s 10th Anniversary SciTech Extravaganza
Come and join us in Glasshouse at Alderley Park for an interactive and inspiring day of science and technology fun, in collaboration with…
Infex to present RESP-X Phase I data at ERS Congress
RESP-X is a potential blockbuster anti-virulence antibody drug to reduce the frequency of debilitating exacerbations in respiratory…
Infex strengthens its senior leadership team
Appointment of Director of Clinical Programmes and changes to senior management team
Infex webinar – broader pipeline and growth strategy
On 9th May 2024, Infex Therapeutics held a live webinar, to update on the company's broader pipeline and growth strategy.
Infex welcomes the UK government’s new five-year plan to combat antimicrobial resistance
Infex Therapeutics, a leading anti-infectives specialist, welcomes the UK government’s new five-year national action plan to help combat…
Infex to present webinar on broader pipeline and growth strategy
Infex Therapeutics, a leading anti-infectives specialist, announces it will be holding a webinar for investors, analysts, and media on 9th…
Webinar on Infex’s Phase II lead respiratory drug, RESP-X
On Jan 31st, Infex Therapeutics held a live webinar, to update on progress with our lead Phase II asset, RESP-X.
Infex to present webinar on lead Phase II respiratory drug RESP-X
RESP-X is a potential blockbuster anti-virulence antibody drug to reduce the frequency of debilitating exacerbations in respiratory…